Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
HeraMED Ltd. ( (AU:HMD) ) just unveiled an update.
HeraMED Limited has reported significant progress in the fourth quarter of FY24, notably with the HeraCARE platform at Broward Health in the U.S., where nine care plans are now active, supporting a variety of maternal health needs. The company has raised $4.1 million in new capital, established strategic partnerships, and begun the integration of HeraCARE into EPIC’s Electronic Medical Records system. These developments are expected to enhance HeraMED’s positioning in the digital maternity care sector, with the potential to expand its market presence and improve outcomes in maternal healthcare.
More about HeraMED Ltd.
HeraMED Limited is a medical data and technology company focused on transforming maternity care through digital innovation. The company’s primary product is the HeraCARE platform, which is designed to improve prenatal and postpartum care by integrating patient data and enhancing care delivery models. HeraMED is actively engaged in strategic partnerships and collaborations to expand its technological reach and value in the maternal healthcare market.
YTD Price Performance: 0.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €9.96M
For a thorough assessment of HMD stock, go to TipRanks’ Stock Analysis page.
